NCT07846943Not yet recruiting
Epstein-Barr Virus Antibodies in Egyptian Patients With Multiple Sclerosis
Frequency and Clinical Significance of Epstein-Barr Virus Antibody Titers in Egyptian Patients With Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 29 Sept 2026
Brief summary (registry, in English)
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system that causes variable degrees of neurological disability. Epstein-Barr virus (EBV) has been identified as an important environmental factor implicated in the pathogenesis and progression of MS. However, the serological profile, antibody titers, and clinical relevance of EBV infection among Egyptian individuals with MS remain limited. The primary purpose of this hospital-based observational study is to evaluate the frequency and titers of EBV-specific antibodies, specifically anti-viral capsid antigen (anti-VCA) IgG and anti-Epstein-Barr virus nuclear antigen 1 (anti-EBNA1) IgG, in Egyptian patients diagnosed with MS compared with age- and sex-matched healthy controls. The study also aims to assess whether EBV antibody levels correlate with MS disease activity, degree of neurological disability, relapse frequency, clinical subtype, brain MRI lesion burden, and response to disease-modifying therapies (DMTs). A total of 140 participants will be enrolled at the Department of Neurology and Psychiatry, Assiut University Hospital, comprising 70 adult patients with MS diagnosed according to the 2024 McDonald criteria and 70 matched healthy controls. Participants will undergo clinical and demographic assessment, neurological disability evaluation using the Expanded Disability Status Scale (EDSS) for MS patients, and review of existing brain MRI scans. A single venous blood sample will be collected from all participants to measure anti-VCA IgG and anti-EBNA1 IgG levels using enzyme-linked immunosorbent assay (ELISA).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 140 (estimated)
- First submitted
- 23 Sept 2026
- Start date
- Oct 2026
- Primary completion date
- Oct 2027
- Lead sponsor
- Assiut University
- Diseases
- Multiple sclerosis
- NCT number
- NCT07846943
What you commit to
- Study type: Observational
- Planned participants: 140
- From Oct 2026 to the primary completion date, Oct 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active or chronic infection with human immunodeficiency virus (HIV) or viral hepatitis.
- Past or current history of malignancy.
- Co-existing systemic immunosuppressive or autoimmune disorders unrelated to multiple sclerosis.
Age
- Individuals younger than 18 years or older than 55 years.
Other
- Pregnancy.
- Inability or unwillingness to provide written informed consent.
Who the study is looking for
- Adult individuals aged 18 to 55 years.
- Confirmed diagnosis of multiple sclerosis according to the 2024 revised McDonald criteria (for the multiple sclerosis cohort).
- Apparently healthy individuals matched by age and sex with no history of neurological disorders (for the healthy control cohort).
- Ability to understand study procedures and provide written informed consent.
Age in the registry: 18 years to 55 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.